DYNAMIC REGULATION OF ADHESIVE FORCES MEDIATED BY AIBB3

Information

  • Research Project
  • 6184692
  • ApplicationId
    6184692
  • Core Project Number
    R01HL061834
  • Full Project Number
    5R01HL061834-03
  • Serial Number
    61834
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1998 - 26 years ago
  • Project End Date
    8/31/2001 - 23 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/2000 - 24 years ago
  • Budget End Date
    8/31/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/22/2000 - 24 years ago

DYNAMIC REGULATION OF ADHESIVE FORCES MEDIATED BY AIBB3

The integrin alphaIIbbeta3 is of key importance in the process of platelet thrombus formation, but the sequence of events that modulate its distinct functions on resting and activated platelets is not yet fully understood. The long term objective of this proposal is to gain insight into the dynamic regulation of the adhesive forces mediated by alphaIIbbeta3 under defined functional conditions. The first experimental model will evaluate receptor interaction with surface-bound ligand in a rapid (spin-on) adhesion assay not involving shear forces. Another method will measure directly the adhesive strength between a cell expressing recombinant alphaIIbbeta3 and a surface bound ligand using the single cell micropipette system. Lastly, the effects of varying shear forces on the functional state of alphaIIbbeta3 will be assessed using the parallel plate laminar flow model system. Recombinant expression of alphaIIbbeta3 on Chinese hamster ovary cells (A5 cells) will allow the detailed study of structure-function relationships by evaluating the effects of specific targeted mutations in relevant domains of the receptor. Moreover, the GP Ib-IX complex has been successfully coexpressed in the same cell with alphaIIbbeta3, thus making it possible to evaluate the synergistic role of these two receptors in supporting adhesion under high shear stress. Two external agonists, an activating monoclonal antibody (AP5 or anti-LIBS-6) and divalent ions, will be used to modulate different functional states of the receptor. To gain insight into the progression of alphaIIbbeta3 through its pathway of activation, the following specific aims are proposed: 1) To define the functional properties of each state of recombinant alphaIIbbeta3; 2) to examine the ligand binding specificities of this receptor with respect to immobilized and soluble ligands and discrete ligand domains; 3) to characterize the functional properties of the receptor under conditions of flow; 4) to establish the role of distinct domains of the receptor, such as cation binding sites, ligand binding sites and cytoplasmic tail sequences, in maintaining the distinct functional states of recombinant alphaIIbbeta3. The results obtained from these studies will contribute to elucidating the mechanism of alphaIIbbeta3 activation; this, in turn, will clarify an important aspect of platelet function during thrombogenesis.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    96209
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:96209\
  • Funding Mechanism
  • Study Section
    HEM
  • Study Section Name
    Hematology Subcommittee 2
  • Organization Name
    MAXIA PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92037
  • Organization District
    UNITED STATES